NASDAQ:TTOO - T2 Biosystems Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.08 -0.09 (-2.16 %)
(As of 12/10/2018 04:00 PM ET)
Previous Close$4.17
Today's Range$3.96 - $4.25
52-Week Range$3.85 - $9.98
Volume287,641 shs
Average Volume540,050 shs
Market Capitalization$183.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC for the direct detection diagnostic test panel that adds additional bacteria species to the existing T2Bacteria product candidate and testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTOO
Previous Symbol
CUSIPN/A
Phone781-761-4646

Debt

Debt-to-Equity Ratio1.66
Current Ratio7.16
Quick Ratio6.81

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.66 million
Price / Sales38.56
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.04 per share
Price / Book102.00

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-62,420,000.00
Net Margins-522.30%
Return on Equity-461.31%
Return on Assets-84.34%

Miscellaneous

Employees161
Outstanding Shares44,040,000
Market Cap$183.64 million
OptionableOptionable

T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) issued its earnings results on Thursday, November, 1st. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.08. The medical equipment provider had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.44 million. T2 Biosystems had a negative net margin of 522.30% and a negative return on equity of 461.31%. The business's revenue was up 127.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.45) earnings per share. View T2 Biosystems' Earnings History.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for T2 Biosystems.

What price target have analysts set for TTOO?

5 brokers have issued twelve-month price targets for T2 Biosystems' shares. Their predictions range from $5.00 to $14.00. On average, they expect T2 Biosystems' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 145.1% from the stock's current price. View Analyst Price Targets for T2 Biosystems.

What is the consensus analysts' recommendation for T2 Biosystems?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for T2 Biosystems.

What are Wall Street analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:
  • 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (11/8/2018)
  • 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage of T2 Biosystems (TTOO) with an Overweight rating and a 12-month price target of $11. We think T2’s direct-from-whole-blood species-specific technology has the potential to change the standard of care for sepsis diagnostics. T2’s diagnostic panels for bacterial and fungal infections deliver a species-specific result in 3-5 hours, compared to 2-5 days for the current standard of care. We foresee favorable emergency department economics as a gateway for hospitals to adopt T2’s technology before a broader rollout to the ICU and sepsis testing more broadly." (9/20/2018)
  • 3. HC Wainwright analysts commented, "We note that T2Bacteria identifies five of the most common and deadly sepsis-causing species of bacteria, has 90% sensitivity and 98% specificity, and is the first FDA-cleared test to identify sepsis-causing bacteria directly from whole blood. Importantly, T2Bacteria provides test results in approximately five hours, which is more than 2.5 days faster than blood culture-dependent tests. This difference in time-to-result is clinically meaningful since rapid targeted treatment based on identification of causative pathogens is critical for clinical outcome, and every hour saved in time to implement a targeted therapy could decrease patient mortality by 8%, according to published literature." (5/30/2018)

Has T2 Biosystems been receiving favorable news coverage?

News coverage about TTOO stock has been trending somewhat positive on Monday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. T2 Biosystems earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the company's share price in the next few days.

Who are some of T2 Biosystems' key competitors?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the folowing people:
  • Mr. John P. McDonough, CEO, Pres & Director (Age 58)
  • Prof. Michael J. Cima, Co-Founder & Director (Age 58)
  • Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 39)
  • Dr. Tyler E. Jacks, Co-Founder (Age 57)
  • Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by many different of retail and institutional investors. Top institutional investors include Senvest Management LLC (6.29%), BlackRock Inc. (4.39%), Vanguard Group Inc. (3.68%), Allianz Asset Management GmbH (1.16%), Renaissance Technologies LLC (0.82%) and Bell Rock Capital LLC (0.66%). Company insiders that own T2 Biosystems stock include Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Institutional Ownership Trends for T2 Biosystems.

Which institutional investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Wells Fargo & Company MN, Emerald Mutual Fund Advisers Trust and Levin Capital Strategies L.P.. Company insiders that have sold T2 Biosystems company stock in the last year include Stanley Lapidus and Thomas J Lowery. View Insider Buying and Selling for T2 Biosystems.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was bought by a variety of institutional investors in the last quarter, including Bell Rock Capital LLC, Allianz Asset Management GmbH, Vanguard Group Inc., BlackRock Inc., Senvest Management LLC, Teachers Advisors LLC, GSA Capital Partners LLP and Trexquant Investment LP. Company insiders that have bought T2 Biosystems stock in the last two years include Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro and Michael Terrence Gibbs. View Insider Buying and Selling for T2 Biosystems.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $4.08.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $183.64 million and generates $4.66 million in revenue each year. T2 Biosystems employs 161 workers across the globe.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is http://www.t2biosystems.com.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]


MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  472
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel